MPM BioImpact Portfolio holdings
MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Context Therapeutics
CNTX
|
+$25.4M |
| 2 |
Zai Lab
ZLAB
|
+$22.2M |
| 3 |
PTC Therapeutics
PTCT
|
+$14.8M |
| 4 |
Scholar Rock
SRRK
|
+$13.6M |
| 5 |
IDEAYA Biosciences
IDYA
|
+$11.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Insmed
INSM
|
+$16.3M |
| 2 |
Madrigal Pharmaceuticals
MDGL
|
+$15.4M |
| 3 |
KalVista Pharmaceuticals
KALV
|
+$10.4M |
| 4 |
Viking Therapeutics
VKTX
|
+$7.66M |
| 5 |
Intellia Therapeutics
NTLA
|
+$5.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
MPM BioImpact's Q4 2024 Portfolio in Review
As of Q4 2024, MPM BioImpact held 54 positions worth $704M, up 5.7% from $667M the previous quarter. Its ten largest holdings account for 45% of the portfolio.
MPM BioImpact deployed $141M of net new capital in Q4 2024, opening 11 new positions and adding to 21 existing holdings. Its largest new stake was Context Therapeutics: 14,705,882 shares worth $15.4M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Insmed, an estimated $16.3M trimmed.
- MPM BioImpact's largest Q4 2024 buy was Context Therapeutics: 14,705,882 shares worth $15.4M.
- MPM BioImpact added most to PTC Therapeutics in Q4 2024, an estimated $14.8M increase.
- MPM BioImpact's biggest Q4 2024 reduction was Insmed, cutting an estimated $16.3M.
- MPM BioImpact fully exited Madrigal Pharmaceuticals in Q4 2024, selling an estimated $15.4M.
- MPM BioImpact's ten largest holdings make up 45% of its $704M portfolio in Q4 2024.
- MPM BioImpact opened 11 new positions and closed 7 in Q4 2024.
- MPM BioImpact's portfolio value rose 5.7% quarter-over-quarter to $704M.
Based on MPM BioImpact's 13F filing for Q4 2024, filed 14 Feb 2025.